Oct 23 (Reuters) - Shares of Gilead Sciences Inc GILD.O rose 6% on Friday after its antiviral drug, remdesivir, became the first and only approved treatment for COVID-19 in the United States.
The U.S. health regulator's approval on Thursday for its use in hospitalized patients came despite the World Health Organization last week saying the drug did not have a substantial effect on patients' length of hospital stay or chances of survival in a global trial.
The U.S. Food and Drug Administration's (FDA) backing signals its confidence in Gilead's U.S.-based study results, which showed the drug was able to cut time to recovery in patients, Piper Sandler analyst Tyler Van Buren said in a client note.
Remdesivir has been available under an FDA emergency use authorization since May, after a study led by the National Institutes of Health showed it reduced hospital stays by five days.
The drug, given intravenously, could generate over $1 billion in sales during the second half of the year at the current case rate, analyst Van Buren said.
Remdesivir, which will be sold under the brand name Veklury, costs $3,120 for a five-day treatment course, or $2,340 for government purchasers such as the Department of Veterans Affairs.
Shares of Gilead were up 5.67% at $64.11 before the bell.
Gilead's remdesivir gets U.S. FDA approval for hospitalized COVID-19 patients
WHO defends data after concluding Gilead's remdesivir flopped COVID trial
Gilead questions WHO study that cast doubts on drug's COVID-19 benefits
FACTBOX-Drugmakers rush to develop COVID-19 treatments
FACTBOX-Countries where remdesivir is approved or supported for treating COVID-19
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
((firstname.lastname@example.org; +91 8061822700;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.